Travere Therapeutics Inc Stock Price, News & Analysis

Travere Therapeutics (NASDAQ: TVTX) announced on January 10, 2022, that its Compensation Committee granted inducement equity to five new employees. This includes stock options for 33,000 shares and RSUs for 9,000 shares, all under the terms of the 2018 Equity Incentive Plan but granted as inducements to employment. The options have an exercise price of $28.04, vesting over four years, while the RSUs also vest over the same period. These grants comply with Nasdaq Listing Rule 5635(c)(4), aimed at attracting and retaining talent in the biopharmaceutical sector.

Travere Therapeutics (NASDAQ: TVTX) announced its expectations for Q4 2021 net product sales of approximately $55 million and total fiscal year 2021 revenues of $227 million. The company is advancing its pipeline, including the investigational drug sparsentan for rare kidney diseases IgA nephropathy and FSGS, with plans for New Drug Applications (NDA) submissions in 2022. Additionally, pegtibatinase is indicated as a potential first treatment for classical homocystinuria. Full financial results are expected to be released in late February.

Travere Therapeutics (NASDAQ: TVTX) appoints Jula Inrig, M.D., as Chief Medical Officer, effective immediately. Dr. Inrig, with over 15 years in drug development, clinical trials, and regulatory engagement, joins the company as it gears up for accelerated approval submissions of sparsentan for IgA nephropathy and focal segmental glomerulosclerosis in 2022. Her extensive background includes executing over 45 clinical trials at IQVIA, leading to FDA and EMA approvals. The company also approved inducement awards of 80,000 stock options and 20,000 restricted stock units as part of her employment package.

Travere Therapeutics (NASDAQ: TVTX) announced positive topline results from its ongoing Phase 1/2 COMPOSE Study of pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). The highest dose cohort (1.5mg/kg BIW) showed a clinically meaningful 55.1% mean reduction in total homocysteine after 12 weeks, maintaining levels below 100 μmol. The treatment was well-tolerated with no discontinuations due to adverse events. The company plans to engage regulators for a pivotal development program to support potential approvals.

Travere Therapeutics (NASDAQ: TVTX) announced the granting of inducement equity grants totaling 71,350 shares to five new employees on December 10, 2021. This includes stock options for 58,500 shares and restricted stock units (RSUs) for 12,850 shares, granted outside the 2018 Equity Incentive Plan. The stock options have an exercise price of $26.76, vesting over four years, while RSUs also vest over four years, contingent on continued employment. These grants are part of the company’s strategy to attract talent within the biopharmaceutical sector.

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) will present a company overview at two upcoming virtual investor conferences in November. The events are the Jefferies 2021 London Healthcare Conference on November 18, 2021, starting at 8:00 a.m. GMT, and the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 10:30 a.m. ET. Live webcasts and archived replays will be available on their investor relations website for up to 30 days.

Travere Therapeutics (NASDAQ: TVTX) announced the presentation of non-clinical data on sparsentan, aimed at protecting kidney function in rare glomerular diseases, at the ASN Kidney Week 2021, from November 4-7, 2021. Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist, is under Phase 3 clinical trials for treating IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). The company achieved significant interim results, showing improvements in proteinuria levels. ePosters will be available online from November 4, 2021, through January 7, 2022.

Travere Therapeutics (TVTX) announced positive interim results from its Phase 3 PROTECT Study of sparsentan for IgA nephropathy, showing a 49.8% reduction in proteinuria compared to 15.1% for irbesartan (p<0.0001). After pre-NDA interactions with the FDA, an NDA submission for sparsentan's accelerated approval is expected in Q1 2022. Additionally, plans for a combined MAA for IgA nephropathy and FSGS in Europe are in place. Q3 2021 net product sales reached $54.2 million, up from $51.1 million in Q3 2020, while the company reported a net loss of $35.6 million for the quarter.

Travere Therapeutics (NASDAQ: TVTX) will announce its third quarter 2021 financial results on October 28, 2021, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a business update. Investors can join the call by dialing +1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International) with confirmation code 5068414. A replay will be available from October 28 until November 4, 2021. Travere aims to offer life-changing therapies for rare diseases.